1.7 million deaths per year are caused by Acute Kidney Injury (AKI) globally. AKI is a frequent clinical event occurring in up to 20% of all hospital patients. Patients with AKI have a significantly higher risk of developing or exacerbating a chronic kidney disease. As of today, an early detection tool for AKI is not available. Nephrolyx aims to close this gap of early detection with an easy-to-use tool for rapid and precise kidney function measurements.

Translating scientific expertise in kidney function measurements to clinical routine, Nephrolyx utilizes a proprietary database, a protocol for contrast agent measurement, and a software to diagnose AKI within the first two to seven hours – reducing the time needed by over tenfold. Nephrolyx is easy to integrate into today’s clinical workflow everywhere and, given low component costs, promises a step-changing improvement in both patient outcomes and healthcare system performance.

Team Nephrolyx unites deep expertise in clinical medicine with focus on nephrology, biomedical and laboratory expertise, biostatistics and machine learning. The project spun off in 2022 as Nephrolytix GmbH to reach their aim to uncover the AKI blind spot.